Loading…
Hemab Therapeutics Holdings, Inc. is projected to rise to $64.39 by 2027, a +36% move from its current price of $47.47. COAG is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/31/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 1 | $44.93 | $47.51 | $50.22 | +0.07% |
| Aug 2 | $43.94 | $47.54 | $51.43 | +0.15% |
| Aug 3 | $43.20 | $47.58 | $52.39 | +0.22% |
| Aug 4 | $42.60 | $47.61 | $53.22 | +0.30% |
| Aug 5 | $42.07 | $47.65 | $53.96 | +0.37% |
| Aug 6 | $41.61 | $47.68 | $54.65 | +0.45% |
| Aug 7 | $41.18 | $47.72 | $55.29 | +0.52% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $41.18 | $47.72 | $55.29 | +0.52% |
| Week 2 | $38.95 | $47.97 | $59.07 | +1.05% |
| Week 3 | $37.36 | $48.22 | $62.23 | +1.58% |
| Week 4 | $36.10 | $48.47 | $65.07 | +2.11% |
| Week 5 | $35.05 | $48.72 | $67.73 | +2.64% |
| Week 6 | $34.15 | $48.98 | $70.26 | +3.18% |
| Week 7 | $33.35 | $49.24 | $72.69 | +3.72% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology company focused on therapies for blood coagulation disorders. It operates in the United States of America and Denmark and is based in Cambridge, Massachusetts.
The company was founded in 2020 and pursues a portfolio that includes HMB-001, a bispecific antibody in Phase 1/2 for the prophylactic treatment of Glanzmann thrombasthenia and Phase 2 for the prophylactic treatment of Factor VII deficiency; and HMB-002, a monovalent antibody in Phase 1/2 for the subcutaneous prophylactic treatment of Von Willebrand disease. It also advances multiple preclinical and discovery-stage assets.
Hemab Therapeutics Holdings, Inc. trades under the ticker COAG and has a current price of $44.75 with a market cap of $2.09B. The stock is ranked 2008 by market capitalization among peers. The current price and market position establish a foundational baseline for the asset as it navigates clinical-stage development in a healthcare-focused sector.
A major floor 63.1% below — a decisive break under it would weaken the trend.
The nearest floor, 44.3% below — buyers have tended to step in here.
The nearest ceiling, 6.2% above — a clean break opens room to run.
A major ceiling 37.7% above — clearing it would confirm fresh momentum.
Key COAG support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of COAG market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $47.44 | Buy | $47.05 | Buy |
| MA 10 | $47.92 | Sell | $46.31 | Buy |
| MA 20 | $42.57 | Buy | $43.18 | Buy |
| MA 50 | $33.84 | Buy | $37.38 | Buy |
| MA 100 | — | Neutral | — | Neutral |
| MA 200 | — | Neutral | — | Neutral |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 61.36 | Neutral |
| Stoch RSI (14) | 19.84 | Buy |
| CCI (20) | 57.36 | Neutral |
| Williams %R (14) | -26.84 | Info |
| MACD (12,26,9) | -0.20 | Sell |
| ROC (12) | 9.61 | Buy |
| Bollinger %B (20,2) | 0.69 | Neutral |
| Stochastic %K (14) | 73.16 | Neutral |
| TRIX (15) | 1.92 | Buy |
| Awesome (5,34) | 10.22 | Buy |
| Ultimate (7,14,28) | 55.36 | Neutral |
| Momentum (10) | 2.94 | Buy |
| Aroon Osc (25) | 84.00 | Buy |
| Hull MA (9) | 46.65 | Buy |
| ADX (14) | 30.18 | Buy |
| ATR (14) | 2.07 | Info |
Technically, the sentiment is BULLISH, with RSI(14) at 60 and a measured 30-day range between $30.85 and $64.92. The stock trades above the 30-day support level of $25.51 and below the resistance at $50.39, placing near-term dynamics within a defined corridor.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $24.98 | $47.47 | $87.00 | 0% | Neutral | |
| $42.32 | $64.39 | $106.01 | +36% | Bullish | |
| $46.76 | $78.97 | $141.77 | +66% | Bullish | |
| $44.03 | $81.58 | $156.22 | +72% | Bullish | |
| $45.03 | $91.06 | $183.77 | +92% | Bullish | |
| $63.51 | $139.81 | $295.03 | +195% | Bullish | |
| $75.75 | $168.34 | $369.39 | +255% | Bullish | |
| $87.84 | $195.19 | $443.45 | +311% | Bullish | |
| $99.15 | $220.34 | $506.78 | +364% | Bullish | |
| $90.96 | $202.13 | $464.90 | +326% | Bullish | |
| $175.44 | $389.86 | $896.68 | +721% | Bullish | |
| $498.64 | $1,108.09 | $2,548.61 | +22.3x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $24.98 | $47.47 | $56.05 | +0.00% |
| August 2026 | $41.43 | $50.69 | $64.89 | +6.78% |
| September 2026 | $40.47 | $50.81 | $67.46 | +0.24% |
| October 2026 | $41.58 | $53.31 | $72.80 | +4.92% |
| November 2026 | $45.13 | $58.88 | $82.24 | +10.46% |
| December 2026 | $46.05 | $61.06 | $87.00 | +3.70% |
Click any year to see its month-by-month COAG forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, COAG could reach as high as $87.00, with a base case around $47.47 and support toward $24.98 — roughly 0% from $47.47. A consolidation phase looks the most probable path here.
Expect COAG to range from $42.32 to $106.01 through 2027. The $64.39 average target implies a +36% move from current prices. That is up +36% on the projected 2026 average. Momentum favours further upside here.
The COAG price prediction for 2028 points to an average of $78.97 (low $46.76, high $141.77) — a potential gain of +66% on today's $47.47. Buyers look set to stay in control over this stretch.
In 2029, COAG is projected to trade between $44.03 and $156.22, averaging $81.58 — a potential gain of +72% from today's $47.47. That is up +3% on the projected 2028 average. Momentum favours further upside here.
Hemab Therapeutics Holdings, Inc.'s 2030 outlook centres on $91.06, within a $45.03 to $183.77 range. That is up +12% on the projected 2029 average. That marks a +92% change versus current levels. Buyers look set to stay in control over this stretch.
By 2031, COAG could reach as high as $295.03, with a base case around $139.81 and support toward $63.51 — roughly +195% from $47.47. Momentum favours further upside here.
Expect COAG to range from $75.75 to $369.39 through 2032. The $168.34 average target implies a +255% move from current prices. That is up +20% on the projected 2031 average. Buyers look set to stay in control over this stretch.
The COAG price prediction for 2033 points to an average of $195.19 (low $87.84, high $443.45) — a potential gain of +311% on today's $47.47. Momentum favours further upside here.
In 2034, COAG is projected to trade between $99.15 and $506.78, averaging $220.34 — a potential gain of +364% from today's $47.47. That is up +13% on the projected 2033 average. Buyers look set to stay in control over this stretch.
Hemab Therapeutics Holdings, Inc.'s 2035 outlook centres on $202.13, within a $90.96 to $464.90 range. That is -8% versus the projected 2034 average. That marks a +326% change versus current levels. Momentum favours further upside here.
By 2040, COAG could reach as high as $896.68, with a base case around $389.86 and support toward $175.44 — roughly +721% from $47.47. Buyers look set to stay in control over this stretch.
Expect COAG to range from $498.64 to $2,548.61 through 2050. The $1,108.09 average target implies a +22.3x move from current prices. That is up +184% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in COAG today (≈ 21.065936 COAG) could be worth
$23,342.94
+$22,342.94 (+2234%) by 2050 · US Dollar
Based on the average projected COAG price of $1,108.09 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in COAGwould be worth at today's price.
$1,000 invested in COAG on May 1, 2026 (≈ 29.411765 COAG) would be worth
$1,396.18
+$396.18 (+39.6%) today · 1.40× · US Dollar
Based on a COAG entry price of $34 vs. today's $47.47.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $45.83 | $1,035.78 | +3.6% |
| 1 month ago | $36.73 | $1,292.4 | +29.2% |
| 3 months ago | $34 | $1,396.18 | +39.6% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our COAG forecast.
Our base-case forecast reaches $95.00 around 2031.
Implied market cap at $95.00: $4.44B
The multi-year forecast shows a path of rising averages and expanding upside. In 2026 the average is $44.75 with a min of $24.98 and a max of $82.33 (ROI 0, sentiment NEUTRAL). By 2030 the average is $86.65 with a max of $174.90 and an ROI of 93.6% (sentiment BULLISH).
The outlook then accelerates to an average of $378.22 in 2040 (ROI 745.2%) and $1,081.65 in 2050 (ROI 2317.1%), both with BULLISH sentiment, illustrating substantial longer-term upside despite inherent uncertainty in clinical-stage execution.
Tap a question to reveal the answer.
In 2030 the forecast shows an average price of $86.65 with a minimum of $42.84 and a maximum of $174.90, and an ROI of 93.6% with bullish sentiment.
The forecast depicts bullish sentiment from 2027 onward, with increases in the average value and rising max targets, culminating in a 2050 average of $1,081.65 and an ROI of 2317.1%. These are estimates and not guarantees, and market conditions can change.
Yes. The 2027 forecast shows a maximum of $100.38, indicating the possibility of hitting or exceeding $100 in that year.
Current price is $44.75 and the market cap is $2.09B.
For 2040 the average is $378.22 with a max of $869.90 and a min of $170.20 (ROI 745.2%). For 2050 the average is $1,081.65 with a max of $2,487.79 and a min of $486.74 (ROI 2317.1%).
Hemab Therapeutics Holdings, Inc. Community Discussion
0Share your Hemab Therapeutics Holdings, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.